List view / Grid view
7 April 2014 | By Amgen
Amgen announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec...
7 April 2014 | By Daiichi Sankyo
Pursuant to the merger transaction announced between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd. announces that it has agreed to vote its shares in Ranbaxy in favor of Sun Pharma’s acquisition of 100%...
7 April 2014 | By Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) announced results from the final analysis of a mirror-image study showing statistically significant reductions (p
7 April 2014 | By Daiichi Sankyo
Attached is the statement of Ranbaxy Laboratories, a subsidiary of Daiichi Sankyo Company, Limited, which was issued on April 7th, 2014...
4 April 2014 | By Novartis
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research...
4 April 2014 | By Merck
Merck announced that it has received an ENERGY STAR 2014 Partner of the Year – Sustained Excellence Award from the U.S...
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
3 April 2014 | By Penn Pharma
Pharmaceutical manufacturer Penn Pharma has announced an agreement with BioAlliance Pharma to manufacture one of their leading development products in Penn’s new contained manufacturing facility...
3 April 2014 | By Karolinska Institutet
A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer...
2 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients...
2 April 2014 | By GlaxoSmithKline
Data from the first patient preference study in advanced renal cell carcinoma are published in the Journal of Clinical Oncology...
1 April 2014 | By Daiichi Sankyo Company
First patient enrolled in largest planned phase 3 study evaluating a novel oral antico-agulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion...
1 April 2014 | By Lundbeck
H. Lundbeck A/S, together with a number of other companies, is now entering into a collaboration with the Lieber Institute, which has the world’s largest collection of human brains from patients with psychiatric disorders...
1 April 2014 | By Shire
Shire plc announced the acceptance of submission of a Marketing Authorisation Application by the European Medicines Agency for their once-daily, non-stimulant guanfacine extended release...
31 March 2014 | By Novartis
Novartis announced that the Data Monitoring Committee unanimously recommended early closure of the PARADIGM-HF study...
